Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Equity (2016 - 2025)

Historic Return on Equity for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to 0.64%.

  • ImmunityBio's Return on Equity fell 1800.0% to 0.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.64%, marking a year-over-year decrease of 1800.0%. This contributed to the annual value of 0.77% for FY2024, which is 3600.0% down from last year.
  • Latest data reveals that ImmunityBio reported Return on Equity of 0.64% as of Q3 2025, which was down 1800.0% from 0.63% recorded in Q2 2025.
  • ImmunityBio's 5-year Return on Equity high stood at 1.88% for Q3 2021, and its period low was 0.63% during Q2 2025.
  • For the 5-year period, ImmunityBio's Return on Equity averaged around 1.06%, with its median value being 0.94% (2024).
  • Per our database at Business Quant, ImmunityBio's Return on Equity crashed by -804600bps in 2021 and then soared by 2200bps in 2023.
  • ImmunityBio's Return on Equity (Quarter) stood at 1.61% in 2021, then tumbled by -41bps to 0.95% in 2022, then increased by 23bps to 1.17% in 2023, then plummeted by -43bps to 0.67% in 2024, then decreased by -5bps to 0.64% in 2025.
  • Its Return on Equity was 0.64% in Q3 2025, compared to 0.63% in Q2 2025 and 0.76% in Q1 2025.